For its first fiscal quarter (ending March 31), Amedisys Inc (NASDAQ: AMED) has reported E.P.S. of $0.44 compared to $0.78 a year ago. E.P.S. were $-0.63 for the latest four quarters through March 31 versus $3.46 for the same period a year ago.
Recent Price Action
Amedisys Inc (NASDAQ: AMED) stock declined slightly by -0.1% on 4/24/24. The stock closed at $91.05. However, this decline was accompanied by exceptionally low trading volume at 28% of normal. The stock has performed in line with the market over the last nine months and is unchanged during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, AMED is expected to continue to be an important Value Builder.
Amedisys has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Amedisys has a poor Appreciation Score of 26 but a neutral Power Rating of 59, and the Negative Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment